• Auxilium Pharmaceuticals Inc., of Malvern, Pa., reported third-quarter revenues of $66.7 million, in line with analyst estimates of $66.8 million. Testim (testosterone gel) for hypogonadism generated $53.6 million and Xiaflex (collagenase clostridium histolyticum) for Dupuytren's contracture generated $13.1 million. Although U.S. Xiaflex revenues were $10.3 million, up 124 percent over the third quarter last year, analysts had expected $11.3 million, and some voiced concerns about Auxilium's ability to meet guidance for the year.